Related Experiment Video
Updated: Feb 1, 2026
03:17
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
1.0K
The past decade in type 2 diabetes and future challenges
Jihad A Haddad1, Aiman N Haddad2
1Center for Endocrinology, Diabetes and Metabolism, Prince Hamzah Hospital, 3034, Amman, 11181, Jordan. Haddad_jihad@yahoo.gr.
Hormones (Athens, Greece)
|December 7, 2018
Summary
Type 2 diabetes mellitus (T2DM) is rising in young people due to obesity. New antidiabetic drugs like SGLT2 inhibitors and GLP-1 agonists show promise in reducing cardiovascular disease (CVD) complications.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Research
- Public Health
Background:
- Rising prevalence of type 2 diabetes mellitus (T2DM), particularly in younger populations, is linked to increased obesity driven by poor diet and sedentary lifestyles.
- Emphasis has shifted towards diabetes-focused cardiovascular outcome trials (CVOTs) due to safety concerns with antidiabetic agents.
Observation:
- Historically, antidiabetic agents primarily demonstrated efficacy in reducing microvascular complications.
- Recent studies reveal that newer drug classes, including SGLT 2 inhibitors and GLP-1 agonists, also effectively reduce major adverse cardiovascular events (MACE).
Findings:
- Newer antidiabetic medications offer dual benefits for glycemic control and cardiovascular risk reduction.
- The therapeutic landscape for T2DM is expanding with agents targeting novel pathophysiologic pathways.
Implications:
- Prevention strategies for T2DM are crucial, alongside effective treatment options.
- Future T2DM treatments aim for enhanced efficacy, improved safety profiles, and targeted action on disease mechanisms to mitigate cardiovascular disease (CVD).
Keywords:
Cardiovascular (CV) outcome trialDipeptidyl peptidase-4 (DPP4) inhibitorsGlucagon-like peptide (GLP-1) agonistsSodium glucose co-transporter 2 (SGLT 2) inhibitorsType 2 diabetes (T2DM)More Related Videos
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
01:20Pathophysiology of Diabetes
3.6K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.6K
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:19Psychoneuroimmunology: Diabetes and Cancer
500
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
500
01:13meta-Directing Deactivators: –NO2, –CN, –CHO, –CO2R, –COR, –CO2H
6.7K
All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for...
6.7K